One operation or two — why it matters

For most patients comparing these two procedures, the most immediate practical question is straightforward: one operation, one recovery — or two operations, two recoveries, several weeks apart? That staging difference is not a logistical footnote; it is the structural core of the AMIC versus MACI comparison and directly affects anaesthetic exposure, time off work, and overall cost.

Both techniques address the same underlying problem: focal, full-thickness cartilage defects in the knee. Articular cartilage has no meaningful blood supply and very limited capacity to repair itself, which is why targeted surgical intervention is needed rather than watchful waiting.

AMIC (Autologous Matrix-Induced Chondrogenesis) accomplishes everything in a single sitting — microfracture of the subchondral bone combined with placement of a bi-layer collagen scaffold, all within one operation. MACI (Matrix-Induced Autologous Chondrocyte Implantation) requires an arthroscopic cartilage biopsy first, then a wait of several weeks while the harvested cells are cultured in a laboratory, followed by a second procedure to implant the cell-seeded scaffold.

Neither approach is categorically superior to the other; defect characteristics, patient circumstances, and surgeon experience all shape the decision. However, for patients in the UK, there is a regulatory reality that narrows the choice considerably: the branded MACI product lost its EU manufacturing authorisation in 2014 and is not available in the UK, whether privately or on the NHS.

How AMIC works in one sitting

During the AMIC procedure, the surgeon first performs microfracture — using an awl or pick to create small perforations through the hard subchondral bone at the base of the cartilage defect. These channels open a pathway to the marrow cavity, releasing bone-marrow-derived stem cells that the body would not otherwise deliver to the cartilage surface.

The second step is what distinguishes AMIC from microfracture alone. A bi-layer collagen type I/III membrane — Chondro-Gide® is the reference product — is shaped to fit the defect and secured over the perforated bone bed. This scaffold acts as a retaining membrane: it holds the stem cells in place at the repair site and provides a three-dimensional framework within which those cells can begin to differentiate and produce repair tissue. Without the scaffold, marrow-derived cells tend to disperse into the joint fluid before meaningful differentiation can occur.

Because the cells come from the patient's own bone marrow — released in the same sitting rather than harvested, cultured, and returned weeks later — no laboratory processing is involved. One anaesthetic, one recovery period.

In the AMIC Registry reported by Gille et al., 57 patients with a mean defect size of 3.4 cm² showed statistically significant reductions in VAS pain scores and functional gains at both one and two years post-operatively (p < 0.001). A retrospective analysis by Schiavoni Panni et al. followed 21 patients to seven years and found sustained benefit for defects larger than 2 cm², suggesting the results hold beyond early follow-up.

One safety signal worth noting: Beck et al. reported extensive subchondral bone cyst formation in a sheep model following microfracture combined with matrix-induced chondrogenesis (Am J Sports Med 2016;44:2629–43). This is a preclinical finding, and long-term human data are still maturing, so it remains an open question rather than an established clinical risk — though it is one reason close imaging follow-up is considered good practice.

How MACI works across two operations

MACI stages the repair across two separate visits to theatre. At the first operation — a short arthroscopic procedure — the surgeon removes a cartilage biopsy of approximately 200–300 mg from the superomedial margin of the femoral trochlea, a non-weight-bearing site chosen to minimise donor-site impact. The sample is preserved at 4°C and transferred to a specialist laboratory, where the chondrocytes are isolated and expanded over several weeks.

The second operation, carried out once sufficient cells have been cultured, implants those cells pre-seeded on a flat type I/III collagen membrane into the prepared defect. The scaffold is secured in place, providing a biological matrix designed to support chondrogenic tissue formation directly at the lesion site.

For patients, the two-stage model carries a concrete burden: two anaesthetic episodes, two post-operative recovery periods, and a symptomatic waiting interval in between during which the untreated knee remains painful.

The clinical evidence for this approach is substantial. The SUMMIT trial demonstrated that MACI produced superior KOOS pain and function scores compared with microfracture at both two and five years for defects of 3 cm² or greater. Longer-term context comes from Minas et al., whose minimum 10-year autologous chondrocyte implantation outcomes confirm that the broader cell-therapy family can deliver durable results in well-selected patients.

Because the branded MACI product is no longer available in the UK — a manufacturing and regulatory matter described in the opening section — patients seeking a cell-based approach here are currently directed towards single-stage alternatives. STACi, offered at the London Cartilage Clinic, processes autologous chondrocytes and bone marrow cells intraoperatively and loads them onto a three-dimensional collagen scaffold within a single operation, removing the weeks-long wait that characterises conventional MACI.

Which defect sizes and patients suit each technique

Defect size is the clearest clinical anchor for matching a patient to either procedure. Both AMIC and MACI occupy roughly the 2–10 cm² window — focal, contained, full-thickness lesions with intact surrounding cartilage and no diffuse joint degeneration. Below approximately 2 cm², osteochondral autograft transfer (OATS or mosaicplasty) or, historically, microfracture alone are more commonly considered first-line; above roughly 10 cm², fresh osteochondral allograft becomes the more appropriate choice, as autologous cell and scaffold approaches are not designed to cover defects of that scale.

Within the shared 2–10 cm² window, some distinctions emerge. The AMIC registry data clustered around a mean defect of 3.4 cm², and seven-year follow-up supports its use particularly in the 2–4 cm² range. The SUMMIT trial, by contrast, demonstrated MACI's superiority over microfracture specifically for defects of 3 cm² or greater — suggesting a particular strength at the upper end of that overlap zone.

The one published head-to-head randomised trial — Fossum et al., 41 patients — compared AMIC against collagen-membrane ACI, not against the matrix-MACI product itself. A clean verdict on which technique outperforms the other across defect sizes therefore does not yet exist. In the zone where both are clinically indicated (roughly 3–4 cm²), the deciding factors tend to be staging preference and UK product availability rather than a clear evidence hierarchy — which is precisely why patient selection and surgeon experience weigh as heavily as defect dimensions alone.

What the evidence actually shows — and where it falls short

Taken together, the two evidence bases are asymmetric in a specific way — and recognising that asymmetry is what allows an honest comparison. MACI's core controlled data come from the SUMMIT trial, designed and powered to detect differences at the defect sizes where the technique is most used. AMIC's strongest controlled evidence is the Fossum RCT, which randomised 41 patients against a collagen-membrane ACI variant — a meaningful result, but one that cannot be transposed directly onto a MACI comparison, because the control arms, patient populations, and outcome instruments differ. The Fossum result supports AMIC's equivalence to ACI-C; it does not rank AMIC against matrix MACI.

That gap — no adequately powered trial randomising equivalent defects to AMIC versus MACI directly — is the honest ceiling of what the current literature can answer. Both techniques demonstrate meaningful clinical benefit in their respective datasets. Neither has been shown superior to the other in a head-to-head comparison.

A practical read of the indirect evidence does, however, support some clinical differentiation. For a first-attempt focal lesion in the 2–4 cm² range, AMIC's single-stage evidence profile is sufficient to support that choice, particularly where surgical staging is a meaningful burden. For defects approaching or exceeding 4–5 cm², or where a prior marrow-stimulation procedure has already altered the subchondral plate, the cell-seeding step carries a biological rationale that becomes difficult to set aside — and that logic, rather than a published comparative hierarchy, is what guides experienced surgeons towards a cell-based approach. The subchondral safety signal identified in preclinical AMIC work remains an open question in long-term human data, adding a further reason to treat the evidence base as evolving rather than settled.

Getting a knee cartilage assessment in Lincolnshire

The choice between AMIC and MACI is not made at the level of preference — it follows from what a structured assessment reveals. Defect size, depth, the condition of the surrounding cartilage, and whether prior marrow-stimulation has altered the subchondral plate all shape which technique, if either, is appropriate. Without that structural picture, the AMIC versus MACI question cannot be answered meaningfully.

MRI is the starting point for that picture. Cartilage-specific sequences — including T2 mapping and segmentation to quantify defect dimensions and surrounding tissue quality — provide the kind of detail that plain imaging cannot. At Lincolnshire Knee (part of the MSK Doctors group), onMRI™ AI-driven analysis supports this characterisation as part of the clinical assessment.

Patients can be seen without a GP referral at clinics in Sleaford (NG34) and Grantham (NG31). To book a knee cartilage assessment, visit lincolnshireknee.co.uk.

1. [1] Knee Cartilage Replacement Therapy. https://en.wikipedia.org/?curid=4984243 https://en.wikipedia.org/?curid=4984243
2. [2] Autologous Chondrocyte Implantation. https://en.wikipedia.org/?curid=19074150 https://en.wikipedia.org/?curid=19074150